Overall rank by patents
#32,622
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 2 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B60R (VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR).
The verdict
NRTV holds 8 US patents across 2 technology areas, rank #32,622 of 50,000 tracked assignees.
NRTV Collab Inc. has been granted 8 US utility patents between 2022 and 2025, placing NRTV Collab Inc. at rank #32,622 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.4 claims per patent with primary concentration in B60R (VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR). As a US Corporation, NRTV Collab Inc. is one of the more focused assignees in the PatentsView dataset. By volume, NRTV sits between Novozymes Biopharma DK A/s (8 patents, rank #32,618) and Nufarm Autralia Limited (8 patents, rank #32,626) - the closest US assignees by grant volume. The composite Innovation Score of 38.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 8 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. NRTV Collab Inc.'s 10.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark NRTV Collab Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NOVOZYMES BIOPHARMA DK A/S
8 patents
NPROXX B.V.
8 patents
NPS PHARMACEUTICALS, INC.
8 patents
NRG Innovations
8 patents
NTECH PROPERTIES, INC.
8 patents
NUCORION PHARMACEUTICALS, INC.
8 patents
NUEON INC.
8 patents
NUFARM AUTRALIA LIMITED
8 patents
NRTV COLLAB INC.
8 patents
What this shows NRTV holds 8 patents at rank #32,622, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #32,622 in granted patent volume.
Other assignees with the most granted patents in NRTV's primary technology class.
NRTV's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
39 Top 40% higher than 60% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 12.5% |
| 2023 | 3 | 37.5% |
| 2024 | 3 | 37.5% |
| 2025 | 1 | 12.5% |
Top 2 of 2 technology areas
Overall rank by patents
#32,622
Across all tracked assignees
38.8 out of 100
How to use this portfolio
NRTV's 8 grants land it in the top 40% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.